Literature DB >> 318975

Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin.

C G Taylor, E Mascarós, J Román, M Paz, M Santos, A Muñoz, M Gobernado.   

Abstract

The effect of calcium salt of fosfomycin in the treatment of 43 neonates suffering from acute gastroenterocolitis produced by enteropathogenic E. coli is evaluated. The minimal inhibitory concentration of these E. coli was, generally, lower than 128 mug/ml. Dosages of 150-200 mg/kg body weight/day were administered orally every 8 h. This treatment lasted for 4 days only. Clinical evolution was favorable in 38 (88%) babies and bacteriological evolution in 30 (70%). In eight cases a different flora to the initial was selected during the treatment with fosfomycin. None of the cases treated showed any toxic alteration attributed to the antibiotic.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318975     DOI: 10.1159/000222068

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

Review 1.  The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

2.  Disposition of phosphomycin in patients with pleural effusion.

Authors:  C F Lastra; E L Mariño; M Barrueco; M S Gervós; A D Gil
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.

Authors:  Christina W Obiero; Phoebe Williams; Sheila Murunga; Johnstone Thitiri; Raymond Omollo; Ann Sarah Walker; Thaddaeus Egondi; Borna Nyaoke; Erika Correia; Zoe Kane; Silke Gastine; Karin Kipper; Joseph F Standing; Sally Ellis; Mike Sharland; James Alexander Berkley
Journal:  Arch Dis Child       Date:  2022-01-25       Impact factor: 4.920

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.